Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Obesity and Overweight

Conditions

Obesity and Overweight, Binge Eating Disorder

Trial Timeline

Sep 17, 2025 → Dec 1, 2027

NCT ID

NCT06847399

About Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)

Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection) is a phase 2 stage product being developed by Eli Lilly for Obesity and Overweight. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06847399. Target conditions include Obesity and Overweight, Binge Eating Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Obesity and Overweight were approved

Approved (20) Terminated (5) Active (0)

✅exenatide + PlaceboEli LillyApproved

✅TirzepatideEli LillyApproved

✅Micafungin + MicafunginAstellas PharmaApproved

✅MicafunginAstellas PharmaApproved

✅Zonegran + PlaceboEisaiApproved

✅lorcaserin hydrochloride XR + PlaceboEisaiApproved

✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06847399	Phase 2	Recruiting	Sep 17, 2025	Dec 1, 2027	Obesity and Overweight

Competing Products

20 competing products in Obesity and Overweight

See all competitors

Product	Company	Stage	Hype Score
MK0493	Merck	Phase 2	35
MK0557	Merck	Phase 3	40
AMG 786	Amgen	Phase 1	29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo	Eli Lilly	Phase 2	39
Tirzepatide	Eli Lilly	Phase 2	42
exenatide + Placebo	Eli Lilly	Approved	43
Brenipatide	Eli Lilly	Phase 1	36
Orforglipron + Placebo	Eli Lilly	Phase 3	47
TERN-601	Terns Pharmaceuticals	Phase 2	32
MBX 4291 + Placebo	MBX Biosciences	Phase 1	30
PG-102	Rani Therapeutics	Phase 1	26
Orforglipron + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
Eloralintide + Placebo	Eli Lilly	Phase 1	29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo	Eli Lilly	Phase 2	27
LY3437943 + Midazolam + Warfarin + Caffeine	Eli Lilly	Phase 1	29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection	Skye Bioscience	Phase 2	29
Tirzepatide	Eli Lilly	Approved	50
Adenosine + Regadenoson	Astellas Pharma	Pre-clinical	26
Micafungin + Micafungin	Astellas Pharma	Approved	43